With global eradication of wild-type polio within sight, but an ongoing risk of outbreaks from vaccine derived viruses (VDPV) one of the final steps of the eradication strategy is to prepare stockpiles of safer novel monovalent poliovirus vaccines for use in outbreak control. Producing such stockpiles presents an opportunity to develop new strains of attenuated polioviruses - whose genetic modifications are more resistant to reversion to neurovirulence in the human intestine - to further decrease the potential of VDPV. As part of the Global Poliovirus Eradication Initiative all serotype 2 polioviruses have been withdrawn, and any further work with polioviruses and live attenuated vaccines must be performed within the constraints of GAPIII. We describe the recently created novel purpose-built contained facility, Poliopolis, to study the immunogenicity, shedding and genetic stability of 2 novel serotype 2 OPV candidates in healthy adult volunteers, which may be a model for future quarantine vaccine studies. To safeguard any potential risk for release into the environment of the vaccine strains, several techniques for elimination or inactivation of the GMO at any time during and at the end of the study were put in place. The design and construction of Poliopolis and the rationale for the different procedures put in place, practical challenges for implementation and results will be discussed.